Dmitry Balyasny’s KalVista Pharmaceuticals KALV Stock Holding History

Dmitry Balyasny’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,098	Closed	-$223K	–	3264
2026 Q1	$223K	Buy	+11,098	New	+$179K	﹤0.01%	2659
2024 Q4	–	Sell	-26,968	Closed	-$312K	–	3009
2024 Q3	$312K	Buy	+26,968	New	+$339K	﹤0.01%	2443
2024 Q1	–	Sell	-11,905	Closed	-$146K	–	2874
2023 Q4	$146K	Buy	11,905 +1,235	+12%	+$11.2K	﹤0.01%	2352
2023 Q3	$103K	Buy	+10,670	New	+$109K	﹤0.01%	2126

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Dmitry Balyasny's KALV Position: Q2 2026 in Review

Dmitry Balyasny sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 11,098 shares — an estimated $223K sold.

Dmitry Balyasny first reported a position in KALV in Q3 2023 and held it in 4 quarters. The position peaked at $312K in Q3 2024. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Dmitry Balyasny reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 11,098 KalVista Pharmaceuticals shares in Q2 2026, an estimated $223K.
Dmitry Balyasny first reported a position in KalVista Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Dmitry Balyasny's KalVista Pharmaceuticals position peaked at $312K in Q3 2024.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.